{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-023428","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.615128+00:00","generated_at":"2026-06-13T12:42:08.108704+00:00","sec_items":["2.02","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biotricity FY23 revenue up 26% to $9.64M, net loss narrows; 1:6 reverse split effective July 3","bullets":["FY23 revenue grew 26% YoY to $9.64M; net loss decreased 35% to $19.5M.","Recurring Technology Fees rose 49% to $8.8M, 71% gross margin; blended margin 57%.","Q4 revenue $2.74M (+28% YoY); net loss $4.9M vs $6.0M a year ago.","1-for-6 reverse split to maintain Nasdaq $1 minimum bid; shares reduce to ~8.5M.","Company targets positive cash flow by end of CY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-023428","json":"https://secwatch.observer/filing/0001493152-23-023428.json","markdown":"https://secwatch.observer/filing/0001493152-23-023428.md","text":"https://secwatch.observer/filing/0001493152-23-023428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/0001493152-23-023428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:42:08.108704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"796864b228f79bc837d5d2a451f212a12bf9ac43","claim":"BIOTRICITY INC. reported fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023 results: revenue $9.64 million, net income $19.5 million, EPS $0.38 per share.","evidence_excerpt":"Cash Flow ● Company advancing toward positive cashflow likely by end of CY 2024 ● Accelerating product sales, and customer re-order revenue, ● FY23 revenue rose 26% YOY to $9.64 million on 5% lower SG&A of $17.6 million ● Improving gross margins currently at 57% despite reduced, loss-leader device pricing to boost recurring ‘Technology Fees,’ lower customers’","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/0001493152-23-023428-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023"},{"label":"Revenue","value":"$9.64 million"},{"label":"Net income","value":"$19.5 million"},{"label":"EPS","value":"$0.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"3123159c6926991616e2bfbc79eaefb8f734e846","claim":"BIOTRICITY INC.: Effected a 1-for-6 reverse stock split via Certificate of Amendment to Amended and Restated Articles of Incorporation (effective 2023-07-03).","evidence_excerpt":"On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six (1-for-6) reverse split (the “Reverse Split”). The Reverse Split became effective on July 3, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223023428/0001493152-23-023428-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-07-03"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}